KR101680385B1 - 올리고머-아릴옥시-치환된 프로판아민 컨쥬게이트 - Google Patents

올리고머-아릴옥시-치환된 프로판아민 컨쥬게이트 Download PDF

Info

Publication number
KR101680385B1
KR101680385B1 KR1020107022518A KR20107022518A KR101680385B1 KR 101680385 B1 KR101680385 B1 KR 101680385B1 KR 1020107022518 A KR1020107022518 A KR 1020107022518A KR 20107022518 A KR20107022518 A KR 20107022518A KR 101680385 B1 KR101680385 B1 KR 101680385B1
Authority
KR
South Korea
Prior art keywords
oligomer
aryloxy
group
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107022518A
Other languages
English (en)
Korean (ko)
Other versions
KR20100132030A (ko
Inventor
제니퍼 릭스-소티어
프랑코 제이 두아트
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20100132030A publication Critical patent/KR20100132030A/ko
Application granted granted Critical
Publication of KR101680385B1 publication Critical patent/KR101680385B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020107022518A 2008-04-11 2009-04-13 올리고머-아릴옥시-치환된 프로판아민 컨쥬게이트 Active KR101680385B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12392908P 2008-04-11 2008-04-11
US61/123,929 2008-04-11
PCT/US2009/002285 WO2009126333A1 (en) 2008-04-11 2009-04-13 Oligomer-aryloxy-substituted propanamine conjugates

Publications (2)

Publication Number Publication Date
KR20100132030A KR20100132030A (ko) 2010-12-16
KR101680385B1 true KR101680385B1 (ko) 2016-11-28

Family

ID=41016853

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022518A Active KR101680385B1 (ko) 2008-04-11 2009-04-13 올리고머-아릴옥시-치환된 프로판아민 컨쥬게이트

Country Status (10)

Country Link
US (1) US9233165B2 (https=)
EP (1) EP2265290B1 (https=)
JP (1) JP5543958B2 (https=)
KR (1) KR101680385B1 (https=)
CN (2) CN101998866A (https=)
AU (1) AU2009234322B2 (https=)
CA (1) CA2720760C (https=)
IL (1) IL208567A (https=)
MX (1) MX2010011101A (https=)
WO (1) WO2009126333A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
CN106478376A (zh) * 2016-10-08 2017-03-08 贵州大学 一种4‑氟萘‑1‑醇的制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057868A1 (en) 2004-11-29 2006-06-01 Eli Lilly And Company Antithrombotic diamides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE372762B (https=) * 1969-05-21 1975-01-13 Haessle Ab
JPS5123488A (https=) 1974-08-21 1976-02-25 Matsushita Electric Industrial Co Ltd
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
MX2007009797A (es) 2005-02-14 2007-11-06 Combinatorx Inc Compuestos y sus usos.
WO2007109564A2 (en) * 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
WO2008112287A1 (en) * 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057868A1 (en) 2004-11-29 2006-06-01 Eli Lilly And Company Antithrombotic diamides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters (2004)*
Journal of Biomaterials Science, Polymer Edition, Vol. 6, o. 2, pp. 133-139 (1994)
Journal of Controlled Release (2001)*

Also Published As

Publication number Publication date
EP2265290B1 (en) 2014-06-04
IL208567A (en) 2015-11-30
CA2720760A1 (en) 2009-10-15
US20110071207A1 (en) 2011-03-24
WO2009126333A1 (en) 2009-10-15
AU2009234322A1 (en) 2009-10-15
EP2265290A1 (en) 2010-12-29
US9233165B2 (en) 2016-01-12
CN105566284A (zh) 2016-05-11
AU2009234322B2 (en) 2014-12-04
JP2011516551A (ja) 2011-05-26
CN101998866A (zh) 2011-03-30
KR20100132030A (ko) 2010-12-16
JP5543958B2 (ja) 2014-07-09
IL208567A0 (en) 2010-12-30
MX2010011101A (es) 2010-11-01
CA2720760C (en) 2016-10-11

Similar Documents

Publication Publication Date Title
JP5827123B2 (ja) 乱用の可能性が低いｐｅｇ化オピオイド
EP2121031B1 (en) Oligomer-antihistamine conjugates
CN103906522B (zh) 阿片激动剂化合物和止痛化合物的组合物、剂型以及共给药
KR101539797B1 (ko) 올리고머-삼환계 콘쥬게이트
WO2009099670A2 (en) Oligomer-cannabinoid conjugates
US8685979B2 (en) Oligomer-diarylpiperazine conjugates
KR101680385B1 (ko) 올리고머-아릴옥시-치환된 프로판아민 컨쥬게이트
CA2749126C (en) Oligomer-phenothiazine conjugates
US8785661B2 (en) Oligome-containing pyrrolidine compounds
KR101799113B1 (ko) 올리고머를 함유하는 치환된 방향족 트리아진 화합물
US9487473B2 (en) Oligomer-amino acid conjugates
US20110009446A1 (en) Oligomer-guanidine class conjugates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101008

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140410

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150910

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20160308

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160908

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20161122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20161122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee